This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
LAKEWOOD, CO / ACCESSWIRE / August 14, 2018 / General Moly, Inc. (the "Company" or "General Moly") (NYSE AMERICAN and TSX: GMO) announced its financial results today for the second quarter ended June 30, 2018. The Company is positioned as the only western-exchange listed, pure-play molybdenum ("moly") development company poised to benefit as the moly spot price has strengthened to $12.23/lb at the date of this release, up 15% since the end of 2Q 2018 and 19% since the end of 2017.
GMO BHI GMO
Oil Price Last week WTI fell a modest 76c and Brent 40c with the EIA inventory stats causing most grief. With a strong dollar and US/Sino and US/Turkish trade wars hotting up downward pressure was exerted but attacks by and on the Yemen kept geopolitics in the frame.
BHI RBD ZEE SOU PPCGF SNEGF PPC CANIF
General Electric (GE) is getting dangerously close to closing at new yearly lows. Potential asset sales for the power conversion unit and digital business are doing nothing to get market participants buying the stock again. Needless to say, GE’s run back to $15 in May did not last. What will it take for the stock to stop making fresh 52-week lows?
BHI GEC GE GNE UTX
Oil prices dipped on Monday as rising trade tensions dented the outlook for fuel demand growth especially in Asia, although US sanctions against Iran still pointed towards tighter supply. Front-month Brent crude oil futures were at $72.63 per barrel at 0509 GMT, down by 18 cents, or 0.25 per cent from their last close.
SINGAPORE (Aug 13): Oil prices dipped on Monday as rising trade tensions dented the outlook for fuel demand growth especially in Asia, although U.S. sanctions against Iran still pointed towards tighter supply.
Good day, everybody and welcome to our earnings call for the second quarter of 2018. I'm joined today by Charlie Ergen, our Chairman; Mike Dugan, our CEO; Dave Rayner, COO and CFO; Pradman Kaul, President of Hughes; Anders Johnson, Chief Strategy Officer and President of EchoStar Satellite Services; and Joe Torres, Associate General Counsel.
SATS BHI ISAT SAVE
In the week ending August 10, 2018, the number of land rigs drilling for oil in the United States totaled 869, up by 10 compared to the previous week and 101 more compared with a total of 768 a year ago. Including 186 other land rigs drilling for natural gas and two listed as miscellaneous, there are a total of 1,057 working rigs in the country, 13 more than a week ago and up by 108 year over year.
HOUSTON (AP) — The number of rigs exploring for oil and natural gas in the U.S. has jumped by 13 this week to 1,057.
9h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
9h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
10h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET